As early as two decades ago, prior to the widespread adoption of FLT3 testing and next-generation sequencing, as most cases of FLT3-mutant AML presented with a normal karyotype, they were therefore classified as intermediate-risk disease. The gene discussed is FLT3; the disease is acute myeloid leukemia.